MAP3K14 and lymphoma: In Mantel cell lymphoma (MCL), an aggressive B-cell malignancy that is refractory to treatment, NIK was identified as a new therapeutic target, particularly for lymphomas that are resistant to B-cell receptor pathway inhibitors [77].